JY
SCNI

Jeff Yass’s Scinai Immunotherapeutics SCNI Stock Holding History

Jeff Yass’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-109
Closed -$14.9K – 12863
2023
Q2 		$14.9K Buy
+109
New +$18.8K ﹤0.01% 11692
2022
Q3 		– Sell
-11
Closed -$13K – 14011
2022
Q2 		$13K Sell
11
-45
-80% -$61.8K ﹤0.01% 12459
2022
Q1 		$94K Buy
+56
New +$81.3K ﹤0.01% 11957
2017
Q2 		– Sell
-14
Closed -$83K – 9753
2017
Q1 		$83K Buy
+14
New +$72.1K ﹤0.01% 8464

Other funds holding SCNI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jeff Yass's SCNI Position: Q3 2023 in Review

Jeff Yass sold out of Scinai Immunotherapeutics (SCNI) in Q3 2023, closing a stake of 109 shares — an estimated $14.9K sold.

Jeff Yass first reported a position in SCNI in Q1 2017 and held it in 4 quarters. The position peaked at $94K in Q1 2022. 7 funds tracked by Wall St. Rank hold SCNI as of Q3 2023.

  • Jeff Yass reported no remaining Scinai Immunotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Jeff Yass sold 109 Scinai Immunotherapeutics shares in Q3 2023, an estimated $14.9K.
  • Jeff Yass first reported a position in Scinai Immunotherapeutics in Q1 2017 and held it in 4 quarters.
  • Jeff Yass's Scinai Immunotherapeutics position peaked at $94K in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.